129 related articles for article (PubMed ID: 7296877)
21. Self-induced correction of the genetic defect in tyrosinemia type I.
Kvittingen EA; Rootwelt H; Berger R; Brandtzaeg P
J Clin Invest; 1994 Oct; 94(4):1657-61. PubMed ID: 7929843
[TBL] [Abstract][Full Text] [Related]
22. A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I.
Grompe M; St-Louis M; Demers SI; al-Dhalimy M; Leclerc B; Tanguay RM
N Engl J Med; 1994 Aug; 331(6):353-7. PubMed ID: 8028615
[TBL] [Abstract][Full Text] [Related]
23. Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors.
Kubo S; Sun M; Miyahara M; Umeyama K; Urakami K; Yamamoto T; Jakobs C; Matsuda I; Endo F
Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9552-7. PubMed ID: 9689118
[TBL] [Abstract][Full Text] [Related]
24. Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity.
Labelle Y; Phaneuf D; Leclerc B; Tanguay RM
Hum Mol Genet; 1993 Jul; 2(7):941-6. PubMed ID: 8364576
[TBL] [Abstract][Full Text] [Related]
25. Tyrosine and its catabolites: from disease to cancer.
Tanguay RM; Jorquera R; Poudrier J; St-Louis M
Acta Biochim Pol; 1996; 43(1):209-16. PubMed ID: 8790725
[TBL] [Abstract][Full Text] [Related]
26. Urinary excretion of deuterated metabolites in patients with tyrosinemia type I after oral loading with deuterated L-tyrosine.
Wadman SK; Duran M; Ketting D; Bruinvis L; van Sprang FJ; Berger R; Smit GP; Steinmann B; Leonard JV; Divry P; Farriaux JP; Cartigny B
Clin Chim Acta; 1983 May; 130(2):231-8. PubMed ID: 6872257
[TBL] [Abstract][Full Text] [Related]
27. Persistent tyrosinemia associated with low activity of tyrosine aminotransferase.
Andersson S; Nemeth A; Ohisalo J; Strandvik B
Pediatr Res; 1984 Jul; 18(7):675-8. PubMed ID: 6147810
[TBL] [Abstract][Full Text] [Related]
28. Type I tyrosinemia: lack of immunologically detectable fumarylacetoacetase enzyme protein in tissues and cell extracts.
Berger R; Van Faassen H; Taanman JW; De Vries H; Agsteribbe E
Pediatr Res; 1987 Oct; 22(4):394-8. PubMed ID: 3317254
[TBL] [Abstract][Full Text] [Related]
29. Prenatal diagnosis of hereditary tyrosinemia by determination of fumarylacetoacetase in cultured amniotic fluid cells.
Kvittingen EA; Steinmann B; Gitzelmann R; Leonard JV; Andria G; Børresen AL; Mossman J; Micara G; Lindblad B
Pediatr Res; 1985 Apr; 19(4):334-7. PubMed ID: 4000758
[TBL] [Abstract][Full Text] [Related]
30. Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone.
Sassa S; Kappas A
J Clin Invest; 1983 Mar; 71(3):625-34. PubMed ID: 6826727
[TBL] [Abstract][Full Text] [Related]
31. Hereditary tyrosinemia type I--an overview.
Kvittingen EA
Scand J Clin Lab Invest Suppl; 1986; 184():27-34. PubMed ID: 3296130
[TBL] [Abstract][Full Text] [Related]
32. The human fumarylacetoacetase gene: characterisation of restriction fragment length polymorphisms and identification of haplotypes in tyrosinemia type 1 and pseudodeficiency.
Rootwelt H; Kvittingen EA; Høie K; Agsteribbe E; Hartog M; van Faassen H; Berger R
Hum Genet; 1992 May; 89(2):229-33. PubMed ID: 1350265
[TBL] [Abstract][Full Text] [Related]
33. Impaired synthesis of taurine in a patient with tyrosinemia type I during the oral L-methionine loading test.
Valík D; Klusácek D; Pintera J
Clin Chim Acta; 1992 Sep; 210(3):227-9. PubMed ID: 1468144
[No Abstract] [Full Text] [Related]
34. Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I.
Grompe M; al-Dhalimy M
Hum Mutat; 1993; 2(2):85-93. PubMed ID: 8318997
[TBL] [Abstract][Full Text] [Related]
35. Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I.
Overturf K; Al-Dhalimy M; Manning K; Ou CN; Finegold M; Grompe M
Hum Gene Ther; 1998 Feb; 9(3):295-304. PubMed ID: 9508047
[TBL] [Abstract][Full Text] [Related]
36. Microassay of tyrosine-amino transferase and p-hydroxyphenylpyruvic acid oxidase in mammalian liver and patients with hereditary tyrosinemia.
Whelan DT; Zannoni VG
Biochem Med; 1974 Jan; 9(1):19-31. PubMed ID: 4150247
[No Abstract] [Full Text] [Related]
37. Six novel mutations in the fumarylacetoacetate hydrolase gene of patients with hereditary tyrosinemia type I.
Timmers C; Grompe M
Hum Mutat; 1996; 7(4):367-9. PubMed ID: 8723690
[No Abstract] [Full Text] [Related]
38. p-hydroxyphenylpyruvate hydroxylase activity in fine-needle aspiration liver biopsies in hereditary tyrosinemia.
Gentz J; Lindblad B
Scand J Clin Lab Invest; 1972 Feb; 29(1):115-26. PubMed ID: 5014992
[No Abstract] [Full Text] [Related]
39. Hereditary tyrosinemia: metabolic studies in a patient with partial p-hydroxyphenylpyruvate hydroxylase activity.
Jagenburg R; Landblad B; De Maré JM; Rödjer S
J Pediatr; 1972 Jun; 80(6):994-1004. PubMed ID: 5026040
[No Abstract] [Full Text] [Related]
40. Biochemical observations on so-called hereditary tyrosinemia.
Gaull GE; Rassin DK; Solomon GE; Harris RC; Sturman JA
Pediatr Res; 1970 Jul; 4(4):337-44. PubMed ID: 4393588
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
